Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
High Blood Pressure & Cardiovascular Prevention
Erschienen in: High Blood Pressure & Cardiovascular Prevention 3/2019

01.06.2019 | Review Article

Vascular Aging and Disease of the Large Vessels: Role of Inflammation

verfasst von: Alessandro Maloberti, Paola Vallerio, Nicola Triglione, Lucia Occhi, Francesco Panzeri, Ilaria Bassi, Francesco Pansera, Enrico Piccinelli, Alessio Peretti, Laura Garatti, Matteo Palazzini, Jinwei Sun, Enzo Grasso, Cristina Giannattasio

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Structural and functional arterial properties commonly impair with aging process. These effects on vasculature could act at many levels from microcirculation to large vessels. Above normal aging process classic cardio-vascular risk factors (hypertension, diabetes mellitus, dyslipidemia, etc.) accelerate the physiological process leading to premature structural and functional alterations that has also been termed early vascular aging. Target organ damage evaluation could be clinically important since these alterations precede by many years’ cardiovascular events and so their assessment can predict the onset of more serious and costly events giving the opportunity to prevent CV events by earlier therapeutic intervention. This review will focus on large artery functional properties and particularly on the role of inflammation on the aortic stiffening process.
Literatur
1.
Nilsson PM, Lurbe E, Laurent S. The early origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens. 2008;26:1049–57.CrossRefPubMed
2.
Iurciuc S, Cimpean AM, Mitu F, Heredea R, Iurciuc M. Vascular aging and subclinical atherosclerosis: why such a “never ending” and challenging story in cardiology? Clin Interv Aging. 2017;12:1339–45.CrossRefPubMedPubMedCentral
3.
Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G, Rietzschel E, Scuteri A, Laurent S. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31(8):1517–26.CrossRefPubMed
4.
Dart AM, Kingwell BA. Pulse pressure—a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001;37(4):975–84.CrossRefPubMed
5.
Lacolley P, Regnault V, Segers P, Laurent S. Vascular smooth muscle cells and arterial stiffening: relevance in development, aging, and disease. Physiol Rev. 2017;97(4):1555–617.CrossRefPubMed
6.
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.CrossRefPubMed
7.
Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–41.CrossRefPubMed
8.
Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636–46.CrossRefPubMed
9.
Chirinos JA, Kips JG, Jacobs JDR, et al. Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis). J Am Col Cardiol. 2012;60:2170–7.CrossRef
10.
Wang KL, Cheng HM, Sung SH, et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study. Hypertension. 2010;55:799–805.CrossRefPubMed
11.
Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2006;37(1):87–92.CrossRefPubMed
12.
Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67.CrossRefPubMed
13.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–605.CrossRefPubMed
14.
Maloberti A, Meani P, Varrenti M, Giupponi L, Stucchi M, Vallerio P, Giannattasio C. Structural and functional abnormalities of carotid artery and their relation with EVA phenomenon. High Blood Press Cardiovasc Prev. 2015;22(4):373–9.CrossRefPubMed
15.
Omboni S, Posokhov IN, Kotovskaya YV, Protogerou AD, Blacher J. Twenty-four-hour ambulatory pulse wave analysis in hypertension management: current evidence and perspectives. Curr Hypertens Rep. 2016;18(10):72.CrossRefPubMed
16.
Shirai K, Shimizu K, Takata M, Suzuki K. Independency of the cardio-ankle vascular index from blood pressure at the time of measurement. J Hypertens. 2017;35(7):1521–3.CrossRefPubMedPubMedCentral
17.
Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, et al. Contradictory effects of β1- and α1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)—CAVI independent of blood pressure. J Atheroscler Thromb. 2011;18:49–55.CrossRefPubMed
18.
Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C, London GM. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transpl. 2014;29(2):232–9.CrossRef
19.
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T, Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–8.CrossRefPubMed
20.
Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksäss A, Van Bortel L, Weber T, Yamashina A, Zimlichman R, Boutouyrie P, Cockcroft J, O’Rourke M, Park JB, Schillaci G, Sillesen H, Townsend RR. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507–32.CrossRefPubMed
21.
22.
Izzo JL Jr, Shykoff BE. Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med. 2001;2:29–34.PubMed
23.
Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43:1239–45.CrossRefPubMed
24.
Lehmann E, Hopkins K, Parker J, et al. Hyperlipidaemia, hypertension and coronary heart disease. Lancet. 1995;345:862–3.CrossRef
25.
Chen Q, Chiheb S, Fysekidis M, et al. Arterial stiffness is elevated in normotensive type 2 diabetic patients with peripheral neuropathy. Nutr Metab Cardiovasc Dis. 2015;25(11):1041–9.CrossRefPubMed
26.
Pannier B, Guérin AP, Marchais SJ, et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension. 2005;45(4):592–6.CrossRefPubMed
27.
Blacher J, Safar ME, Guerin AP, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63(5):1852–60.CrossRefPubMed
28.
Blacher J, Guerin A, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal failure. Circulation. 1999;99:2434–9.CrossRefPubMed
29.
Stefanadis C, Tsiamis E, Vlachopoulos C, et al. Unfavorable effect of smoking on the elastic properties of the aorta. Circulation. 1997;95:31–8.CrossRefPubMed
30.
Maloberti A, Cesana F, Hametner B, Dozio D, Villa P, Hulpke-Wette M, Schwarz A, Selicorni A, Wassertheurer S, Mancia G, Giannattasio C. Increased nocturnal heart rate and wave reflection are early markers of cardiovascular disease in Williams-Beuren syndrome children. J Hypertens. 2015;33(4):804–9.CrossRefPubMed
31.
Cesana F, Nava S, Menni C, Boffi L, Varrenti M, Meani P, Maloberti A, Grassi G, Giannattasio C, Mancia G. Does the 9p region affect arterial stiffness? Results from a cohort of hypertensive individuals. Blood Press. 2013;22(5):302–6.CrossRefPubMed
32.
Benetos A, Adamopoulos C, Bereau JM, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105(10):1202–7.CrossRefPubMed
33.
AlGhatrif M, Strait JB, Morrell CH, et al. Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension. 2013;62(5):934–41.CrossRefPubMed
34.
Ait-Oufella H, Collin C, Bozec E, et al. Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28(11):2336–41.CrossRefPubMed
35.
Safar ME, Thomas F, Blacher J, et al. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol. 2006;47(1):72–5.CrossRefPubMed
36.
Meani P, Maloberti A, Sormani P, Colombo G, Giupponi L, Stucchi M, Varrenti M, Vallerio P, Facchetti R, Grassi G, Mancia G, Giannattasio C. Determinants of carotid-femoral pulse wave velocity progression in hypertensive patients over a 3.7 years follow-up. Blood Press. 2018;27(1):32–40.CrossRefPubMed
37.
O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50:1–13.CrossRefPubMed
38.
Lakatta E, Wang M, Najjar SS. Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am. 2009;93:583–604.CrossRefPubMedPubMedCentral
39.
Cameron AC, Lang NN, Touyz RM. Drug treatment of hypertension: focus on vascular health. Drugs. 2016;76(16):1529–50.CrossRefPubMed
40.
Ichihara A, Hayashi M, Koura Y, et al. Long-term effects of intensive blood pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens. 2003;16:959–65.CrossRefPubMed
41.
Nakamura Y, Fujii S, Hoshino J, et al. Selective angiotensin receptor antagonisms with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res. 2005;28:937–43.CrossRefPubMed
42.
Ting CT, Chen CH, Chang MS, et al. Short- and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension. 1995;26:524–30.CrossRefPubMed
43.
Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke. 1999;30:1056–64.CrossRefPubMed
44.
D’elia L, La Fata E, Iannuzzi A, Rubba PO. Effect of statin therapy on pulse wave velocity: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2018;40:601–8.CrossRefPubMed
45.
Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: a systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017;227:338–41.CrossRefPubMed
46.
Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation and fibrosis. Hypertension. 2001;38:581–7.CrossRefPubMed
47.
Mozos I, Luca CT. Crosstalk between oxidative and nitrosative stress and arterial stiffness. Curr Vasc Pharmacol. 2017;15:446–56.CrossRefPubMed
48.
Schiffrin EL. Immune modulation of resistance artery remodelling. Basic Clin Pharmacol Toxicol. 2012;110:70–2.CrossRefPubMed
49.
50.
51.
Jain S, Khera R, Corrales-Medina VF, Townsend RR, Chirinos JA. Inflammation and arterial stiffness in humans. Atherosclerosis. 2014;237:381–90.CrossRefPubMed
52.
Iacobellis G, Sharma AM, Pellicelli AM, et al. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res. 2007;5(2):275–9.CrossRefPubMed
53.
Fitch Kathleen V, Lo Janet, Abbara Suhny, et al. Increased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters. J Acquir Immune Defic Syndr. 2010;55(4):495–9.CrossRefPubMedPubMedCentral
54.
Maloberti A, Riva M, Tadic M, Valena C, Villa P, Boggioni I, Pozzi MR, Grassi G. Association between atrial, ventricular and vascular morphofunctional alterations in rheumatoid arthritis. High Blood Press Cardiovasc Prev. 2018;25(1):97–104.CrossRefPubMed
55.
Vazques-Del Marcado M, Gomez-Banuelos E, Chavarria-Avila E, Cardona-Muñoz E, Ramos-Becerra C, Alanis-Sanchez A, Cardona-Muller D, Grover-Paez F, Perez-Vazquez FJ, Navarro-Hernandez RE, Valadez-Soto JM, Saldaña-Millan AA, Gonzalez-Rosas L, Ramos-Lopez G, Petri MH, Bäck M. Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross sectional study in patients without known comorbities: a STROBE compliant article. Medicine. 2017;96:e7862.CrossRef
56.
Booth AD, Wallace S, McEniery CM, Brown J, Jayne DR, Wilkinson IB. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum. 2004;50:581–8.CrossRefPubMed
57.
Zanoli L, Boutouyrie P, Fatuzzo P, Granata A, Lentini P, Oztürk K, Cappello M, Theocharidou E, Tuttolomondo A, Pinto A, Cammà C, Licata A, Blanco J, Rastelli S, Inserra G, Castellino P, Laurent S. Inflammation and aortic stiffness: an individual participant data meta-analysis in patients with inflammatory bowel disease. J Am Heart Assoc. 2017;6:e007003.CrossRefPubMedPubMedCentral
58.
Saves M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency compared with the general population. Clin Infect Dis. 2003;37:292–8.CrossRefPubMed
59.
Oliviero U, Bonadies G, Apuzzi V, et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis. 2009;204:586–9.CrossRefPubMed
60.
Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177–87.PubMed
61.
Jiang J, Fu W, Wang X, et al. HIV gp120 induces endothelial dysfunction in tumour necrosis factor-a activated porcine and human endothelial cells. Cariovasc Res. 2010;87(2):366–74.CrossRef
62.
Hurlimann D, Weber R, Enseleit F, et al. HIV infection, antiretroviral therapy, and endothelium. Herz. 2005;30:472–80.CrossRefPubMed
63.
Maloberti A, Giannattasio C, Dozio D, Betelli M, Villa P, Nava S, Cesana F, Facchetti R, Giupponi L, Castagna F, Sabbatini F, Bandera A, Gori A, Grassi G, Mancia G. Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function. Metab Syndr Relat Disord. 2013;11(6):403–11.CrossRefPubMed
64.
Mulè G, Mulè GJ, Geraci G, Colletti P, Mazzola G, Colomba C, Cottone S, Cascio A. Influence of HIV infection and antiretroviral therapy on aortic stiffness: a meta-analysis. J Hypertens. 2018;26:e236.CrossRef
65.
Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J, Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46:350–7.CrossRef
66.
Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin. Rheumatology. 2005;44:1473–82.CrossRefPubMed
67.
Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O’Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50:1734–9.CrossRefPubMed
68.
Ambrosino P, Tasso M, Lupoli R, Di Minno A, Baldassarre D, Tremoli E, Di Minno MN. Non-invasive assessment of arterial stiffness in patients with rheumatoid arthritis: a systematic review and meta-analysis of literature studies. Ann Med. 2015;47:457–67.CrossRefPubMed
69.
Haskard DO. Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol. 2004;33:281–92.CrossRefPubMed
70.
Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum. 2012;41:669–75.CrossRefPubMed
71.
Viazzi F, Leoncini G, Ratto E, Pontremoli R. Serum uric acid as risk factor for cardiovascular and renal disease: an old controversy revived. J Clin Hypertens. 2006;5:510–8.CrossRef
72.
Agabiti Rosei E, Grassi G. Uric acid and cardiovascualr diseases. Curr Med Res Opin. 2013;29(Suppl 3):33–9.CrossRefPubMed
73.
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729–41.CrossRefPubMed
74.
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–41.CrossRefPubMed
75.
Cuspidi C, Valerio C, Sala C, Meani S, Esposito A, Zanchetti A, Mancia G. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens. 2007;20:678–85.CrossRefPubMed
76.
Baena CP, Lotufo PA, Mill JG, Cunha Rde S, Benseñor IJ. Serum uric acid and pulse wave velocity among healthy adults: baseline data from the brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Am J Hypertens. 2015;28:966–70.CrossRefPubMed
77.
Gómez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, Agudo-Conde C, Rodríguez-Sánchez E, Gómez-Sánchez L, Vasorisk group, et al. Relationship between uric acid and vascular structure and function in hypertensive patients and sex-related differences. Am J Hypertens. 2013;26(5):599–607.CrossRefPubMed
78.
Mehta T, Nuccio E, McFann K, Madero M, Sarnak MJ, Jalal D. Association of uric acid with vascular stiffness in the framingham heart study. Am J Hypertens. 2015;28(7):877–83.CrossRefPubMed
79.
Mulè G, Riccobene R, Castiglia A, D’Ignoto F, Ajello E, Geraci G, et al. Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients. Nutr Metab Cardiovasc Dis. 2014;24(7):744–50.CrossRefPubMed
80.
Maloberti A, Maggioni S, Occhi L, Triglione N, Panzeri F, Nava S, Signorini S, Falbo R, Casati M, Grassi G, Giannattasio C. Sex-related relationships between uric acid and target organ damage in hypertension. J Clin Hypertens (Greenwich). 2018;20(1):193–200.CrossRef
81.
Canepa M, Viazzi F, Strait JB, Ameri P, Pontremoli R, Brunelli C, et al. Longitudinal association between serum uric acid and arterial stiffness: results from the baltimore longitudinal study of aging. Hypertension. 2017;69(2):228–35.CrossRefPubMed
82.
Ding XH, Wang X, Cao R, Yang X, Xiao W, Zhang Y, et al. A higher baseline plasma uric acid level is an independent predictor of arterial stiffness: a community-based prospective study. Medicine (Baltimore). 2017;96(6):e5957.CrossRefPubMedPubMedCentral
83.
Nagano S, Takahashi M, Miyai N, Oka M, Utsumi M, Shiba M, et al. Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects. Hypertens Res. 2017;40(6):620–4.CrossRefPubMed
84.
Kotliar C, Kempny Y, Gonzalez S, Castellaro C, Forcada P, Obregon S, et al. Lack of RAAS inhibition by high-salt intake is associated with arterial stiffness in hypertensive patients. J Renin Angiotens Aldosterone Syst. 2014;15:498–504.CrossRef
85.
Madlala HP, Maarman GJ, Ojuka E. Uric acid and transforming growth factor in fructose-induced production of reactive oxygen species in skeletal muscle. Nutr Rev. 2016;74:259–66.CrossRefPubMedPubMedCentral
86.
Kruger R, Mothae M, Smith W. Yia 03-07 reactive oxygen species adversely relates to early vascular changes and arterial stiffness in black normotensive smokers: the African-Predict Study. J Hypertens. 2016;34:e205–6.CrossRef
87.
De Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, Slart RHJA, Lefrandt JD, Mulder DJ. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017;19(8):1147–54.CrossRefPubMed
88.
Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.CrossRefPubMedPubMedCentral
89.
Dell’Oro R, Maloberti A, Nicoli F, Villa P, Gamba P, Bombelli M, Mancia G, Grassi G. Long-term saxagliptin treatment improves endothelial function but not pulse wave velocity and intima-media thickness in type 2 diabetic patients. High Blood Press Cardiovasc Prev. 2017;24(4):393–400.CrossRefPubMed
90.
Baroni M, Nava S, Giupponi L, Meani P, Panzeri F, Varrenti M, Maloberti A, Soriano F, Agrati AM, Ferraro G, Colombo F, Rampoldi A, Mancia G, Colombo P, Klugmann S, Giannattasio C. Effects of renal sympathetic denervation on arterial stiffness and blood pressure control in resistant hypertensive patients: a single centre prospective study. High Blood Press Cardiovasc Prev. 2015;22:411–6.CrossRefPubMed
91.
Gronda E, Brambilla G, Seravalle G, Maloberti A, Cairo M, Costantino G, Lovett E, Vanoli E, Mancia G, Grassi G. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. Clin Res Cardiol. 2016;105:838–46.CrossRefPubMed
92.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.CrossRefPubMedPubMedCentral
93.
Hirshberg B, Katz A. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. Curr Diab Rep. 2015;15:87.CrossRefPubMed
94.
Grassi G, Seravalle G, Brambilla G, Cesana F, Giannattasio C, Mancia G. Similarities and differences between renal sympathetic denervation and carotid baroreceptor stimulation. Curr Vasc Pharmacol. 2014;12:63–8.CrossRefPubMed
95.
Grassi G, Seravalle G, Quarti-Trevano F. The ‘neuroadrenergic hypothesis’ in hypertension: current evidence. Exp Physiol. 2010;95(5):581–6.CrossRefPubMed
96.
Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10–5.CrossRefPubMed
97.
Sehestedt T, Jeppesen J, Hansen TW, et al. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens. 2009;27:2351–7.CrossRefPubMed
98.
Mitchell GF, Hwang SK, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121:505–11.CrossRefPubMedPubMedCentral
99.
Mattace-Raso FU, Van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–63.CrossRefPubMed
100.
The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31:2338–50.CrossRefPubMedCentral
101.
Laurent S, Briet M, Boutouyrie P. Arterial stiffness as surrogate end point: needed clinical trials. Hypertension. 2012;60:518–22.CrossRefPubMed
Metadaten
Titel
Vascular Aging and Disease of the Large Vessels: Role of Inflammation
verfasst von
Alessandro Maloberti
Paola Vallerio
Nicola Triglione
Lucia Occhi
Francesco Panzeri
Ilaria Bassi
Francesco Pansera
Enrico Piccinelli
Alessio Peretti
Laura Garatti
Matteo Palazzini
Jinwei Sun
Enzo Grasso
Cristina Giannattasio
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 3/2019
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-019-00318-4

Weitere Artikel der Ausgabe 3/2019

High Blood Pressure & Cardiovascular Prevention 3/2019 Zur Ausgabe

Commentary

Commentary to “The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease”

Review article

Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors

Original article

Chinese Physicians’ Perspectives on the 2017 American College of Cardiology/American Heart Association Hypertension Guideline: A Mobile App-Based Survey

Original Article

Prevalence and Risk Factors of Hypertension in the Vietnamese Elderly

Original Article

Avoidable Burden of Cardiovascular Diseases in the Eastern Mediterranean Region: Contribution of Selected Risk Factors for Cardiovascular-Related Deaths

Original Article

Morning Surge and Peak Morning Ambulatory Blood Pressure Versus Automated Office Blood Pressure in Predicting Cardiovascular Disease

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise